Processing

Please wait...

Settings

Settings

Goto Application

1. WO2005100992 - MTEHOD OF EXAMINING DISEASE WITH CEREBRAL DYSFUNCTION, PROTEIN MARKER TO BE USED THEREIN, DIAGNOSTIC AGENT AND DIAGNOSTIC KIT

Publication Number WO/2005/100992
Publication Date 27.10.2005
International Application No. PCT/JP2005/006304
International Filing Date 31.03.2005
IPC
G01N 33/53 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
G01N 33/535 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
531Production of immunochemical test materials
532Production of labelled immunochemicals
535with enzyme label
G01N 33/577 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
577involving monoclonal antibodies
CPC
G01N 33/6872
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
G01N 33/6896
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6893related to diseases not provided for elsewhere
6896Neurological disorders, e.g. Alzheimer's disease
Applicants
  • 国立大学法人千葉大学 NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY [JP]/[JP] (AllExceptUS)
  • 藤井 克則 FUJII, Katsunori [JP]/[JP] (UsOnly)
Inventors
  • 藤井 克則 FUJII, Katsunori
Agents
  • 林 佳輔 HAYASHI, Keisuke
Priority Data
2004-13486901.04.2004JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) MTEHOD OF EXAMINING DISEASE WITH CEREBRAL DYSFUNCTION, PROTEIN MARKER TO BE USED THEREIN, DIAGNOSTIC AGENT AND DIAGNOSTIC KIT
(FR) PROCEDE D'EXAMEN DE MALADIE AVEC DYSFONCTIONNEMENT CEREBRAL, MARQUEUR PROTEINE A UTILISER DANS CE PROCEDE, AGENT DE DIAGNOSTIC ET KIT DE DIAGNOSTIC
(JA) 脳機能障害性疾患の検査方法、それに用いるタンパク質マーカ、診断薬および診断キット
Abstract
(EN)
A method of examining a disease with cerebral dysfunction, in particular influenza encephalitis, with the use of a 14-3-3 protein in human cerebrospinal fluid as an indication. In the case where isoforms of the 14-3-3 protein are detected in the order of strength of &bgr;, &thetas;, ϝ, &zgr; and ϵ in the above-described examination method, for example, the subject is diagnosed as having influenza encephalitis. To detect the 14-3-3 protein, it is preferable to use an antibody capable of specifically binding to the protein. It is preferable that the antibody is a monoclonal antibody.
(FR)
Cette invention se rapporte à un procédé d'examen d'une maladie avec dysfonctionnement cérébral, en particulier l'encéphalite grippale, grâce à l'utilisation d'une protéine 14-3-3 dans le liquide céphalo-rachidien humain comme indication. Dans le cas où des isoformes de la protéine 14-3-3 sont détectées dans l'ordre d'importance de $g(b), $g(u), $g(g), $g(j) et $g(e) dans le procédé d'examen décrit ci-dessus, par exemple, le sujet est diagnostiqué avec une encéphalite grippale. Pour détecter la protéine 14-3-3, il est préférable d'utiliser un anticorps capable de se lier spécifiquement à cette protéine. Il est préférable que l'anticorps soit un anticorps monoclonal.
(JA)
 本発明は、ヒト髄液中の14-3-3タンパク質を指標とすることで、脳機能障害性疾患、特に、インフルエンザ脳症を検査する方法である。本発明の検査方法において、例えば、前記14-3-3タンパク質のアイソフォームが、β、θ、γ、ζおよびεの順で強く検出された場合、インフルエンザ脳症と判定する。前記14-3-3タンパク質の検出には、前記タンパク質に対し特異的に結合可能な抗体を使用することが好ましい。前記抗体は、モノクローナル抗体であることが好ましい。
Also published as
Latest bibliographic data on file with the International Bureau